By Bette Flagler
Monday 1st December 2003
|Text too small?|
Launched on 14 October at the annual conference of the New Zealand Grassland Association, Grasslanz has evolved from the Cultivar Development and Management Unit (CDMU) and will carry on with the development and commercialisation of plant technologies, including endophytes and plant cultivars of rye grass, white clover and tall fescue. Stewart says that with only eight employees, Grasslanz is a small company that can take products to market faster than, for instance, a big concern like AgResearch. He also sees the new business arrangement - one step further away from government - as a positive move for taking on outside business partners, stating that, "the company can't develop more products on its current revenue. The future biotechnologies are very exciting stuff, and we will be looking to grow the business through expansion in domestic and international markets, technology and business partnerships. Grasslanz has a strong hold in Australasia on the pasture seed business, and has the capacity to deliver that throughout the world. It's very exciting for big companies like Monsanto, who controls 90% of the transgenics, to find a seed company like Grasslanz."
Stewart is excited about the state of biotechnology in New Zealand in general and is looking to drive the company into diversifications that can be applicable across many species. The board of Grasslanz is expected to be named by the end of November. Celentis has nine other subsidiaries, including AgVax Development, Bio Products, Time Capsule, ComOne and Covita.
No comments yet
Pushpay buys Colorado rival for US$87.5m
Xero chair to retire early as family’s health comes first
Business leaders quiz finance minister on capacity to spend $12b
House prices are accelerating again, even in Auckland
13th December 2019 Morning Report
Tourists still coming but growth is slowing
Peters backs StuffME merger bid
Supplements, skincare firm poised for reverse listing
NZX, EEX eye carbon auction opportunity
A2 Milk boss steps down, shares fall 7.7%